

Actualités de la prise en charge hémodynamique initiale

CONFERENCE REPORTS AND EXPERT PANEL



Surviving Sepsis Campaign:
International Guidelines for Management
of Sepsis and Septic Shock: 2016

Daniel De Backer

**Head Dept Intensive Care, CHIREC hospitals, Belgium
Professor of Intensive Care, Université Libre de Bruxelles
Past- President European Society of Intensive Care Medicine**


CONFERENCE REPORTS AND EXPERT PANEL



Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Andrew Rhodes^{1*}, Laura E. Evans², Waleed Alhazzani³, Mitchell M. Levy⁴, Massimo Antonelli⁵, Ricard Ferrer⁶, Anand Kumar⁷, Jonathan E. Sevransky⁸, Charles L. Sprung⁹, Mark E. Nunnally², Bram Rochweg³, Gordon D. Rubenfeld¹⁰, Derek C. Angus¹¹, Djillali Annane¹², Richard J. Beale¹³, Geoffrey J. Bellinghan¹⁴, Gordon R. Bernard¹⁵, Jean-Daniel Chiche¹⁶, Craig Coopersmith⁸, Daniel P. De Backer¹⁷, Craig J. French¹⁸, Seitaro Fujishima¹⁹, Herwig Gerlach²⁰, Jorge Luis Hidalgo²¹, Steven M. Hollenberg²², Alan E. Jones²³, Dilip R. Karnad²⁴, Ruth M. Kleinpell²⁵, Younsuk Koh²⁶, Thiago Costa Lisboa²⁷, Flavia R. Machado²⁸, John J. Marini²⁹, John C. Marshall³⁰, John E. Mazuski³¹, Lauralyn A. McIntyre³², Anthony S. McLean³³, Sangeeta Mehta³⁴, Rui P. Moreno³⁵, John Myburgh³⁶, Paolo Navalesi³⁷, Osamu Nishida³⁸, Tiffany M. Osborn³¹, Anders Perner³⁹, Colleen M. Plunkett²⁵, Marco Ranieri⁴⁰, Christa A. Schorr²², Maureen A. Seckel⁴¹, Christopher W. Seymour⁴², Lisa Shieh⁴³, Khalid A. Shukri⁴⁴, Steven Q. Simpson⁴⁵, Mervyn Singer⁴⁶, B. Taylor Thompson⁴⁷, Sean R. Townsend⁴⁸, Thomas Van der Poll⁴⁹, Jean-Louis Vincent⁵⁰, W. Joost Wiersinga⁴⁰, Janice L. Zimmerman⁵¹ and R. Phillip Dellinger²⁷

© 2017 SCCM and ESICM



The Intensive Connection

VIEWPOINT

Surviving Sepsis Guidelines

A Continuous Move Toward Better Care of Patients With Sepsis

Daniel De Backer, MD
Department of
Intensive Care, CHIREC
Hospitals, Université
Libre de Bruxelles,
Brussels, Belgium.

Todd Dorman, MD,


Sepsis is a life-threatening condition that affects more than 1 million patients a year in the United States and even more patients around the globe and is one of the leading causes of death. Since the Declaration of Barcelona in 2002, the European Society of Intensive Care Medicine and the Society of Critical Care Medicine (SCCM) have launched several initiatives to decrease

cases; for example, those with a history of cardiac dysfunction who develop pneumonia, when the nature of circulatory failure is not always obvious).

Another important advance is that the new guidelines recommend the use of dynamic (ie, pulse or stroke volume variations induced by mechanical ventilation or passive leg raise test) over static variables (in-

Mitchell M. Levy
Andrew Rhodes
Gary S. Phillips
Sean R. Townsend
Christa A. Schorr
Richard Beale
Tiffany Osborn
Stanley Lemeshow
Jean-Daniel Chiche
Antonio Artigas
R. Phillip Dellinger

Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study



29470 septic pts

Voluntary submission of data

ORIGINAL ARTICLE

Time to Treatment and Mortality during Mandated Emergency Care for Sepsis

Christopher W. Seymour, M.D., Foster Gesten, M.D., Hallie C. Prescott, M.D., Marcus E. Friedrich, M.D., Theodore J. Iwashyna, M.D., Ph.D., Gary S. Phillips, M.A.S., Stanley Lemeshow, Ph.D., Tiffany Osborn, M.D., M.P.H., Kathleen M. Terry, Ph.D., and Mitchell M. Levy, M.D.

| Bundle | Eligible | Elements |
|--------|--|---|
| 3-hour | Severe sepsis or septic shock | Administration of antibiotics within 1 hour of protocol initiation * |
| | | Drawing blood cultures prior to administration of antibiotics |
| | | Measurement of blood lactate within 3 hours of protocol initiation |
| 6-hour | Above plus hypotension (SBP<90) or serum lactate ≥4.0 mmol/L | Administration of a 30cc/kg intravenous fluid bolus |
| | | Administration of vasopressors for refractory hypotension |
| | | Re-measurement of serum lactate within 6 hours of protocol initiation |

NY state
49331 pts
149 hosp


Mandatory reporting

ORIGINAL ARTICLE

Time to Treatment and Mortality during Mandated Emergency Care for Sepsis

Christopher W. Seymour, M.D., Foster Gesten, M.D., Hallie C. Prescott, M.D.,
 Marcus E. Friedrich, M.D., Theodore J. Iwashyna, M.D., Ph.D.,
 Gary S. Phillips, M.A.S., Stanley Lemeshow, Ph.D., Tiffany Osborn, M.D., M.P.H.,
 Kathleen M. Terry, Ph.D., and Mitchell M. Levy, M.D.

NY state
49331 pts
149 hosp





HEMODYNAMIC RESUSCITATION



Surviving Sepsis Campaign:
International Guidelines for Management
of Sepsis and Septic Shock: 2016

Rhodes et al
ICM 2017
CCM 2017


A. INITIAL RESUSCITATION

2. We recommend that, in the resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 h (strong recommendation, low quality of evidence).

Not too much but also not limited....

Liu V et al
Annals ATS 2013

9190 pts with sepsis



ORIGINAL ARTICLE


Time to Treatment and Mortality during Mandated Emergency Care for Sepsis

Christopher W. Seymour, M.D., Foster Gesten, M.D., Hallie C. Prescott, M.D., Marcus E. Friedrich, M.D., Theodore J. Iwashyna, M.D., Ph.D., Gary S. Phillips, M.A.S., Stanley Lemeshow, Ph.D., Tiffany Osborn, M.D., M.P.H., Kathleen M. Terry, Ph.D., and Mitchell M. Levy, M.D.

NEJM 2017

Caution: the delay in fluid administration may be related to lower initial severity

**NY state
49331 pts
149 hosp**




ORIGINAL ARTICLE

Time to Treatment and Mortality during Mandated Emergency Care for Sepsis

Christopher W. Seymour, M.D., Foster Gesten, M.D., Hallie C. Prescott, M.D.,
 Marcus E. Friedrich, M.D., Theodore J. Iwashyna, M.D., Ph.D.,
 Gary S. Phillips, M.A.S., Stanley Lemeshow, Ph.D., Tiffany Osborn, M.D., M.P.H.,
 Kathleen M. Terry, Ph.D., and Mitchell M. Levy, M.D.

| Model | No. | Odds ratio | 95%CI |
|-----------------------------|--------|------------|-----------|
| All cases | 49,331 | 1.01 | 0.99-1.02 |
| Gender | | | |
| Male | 25,689 | 1.00 | 0.98-1.02 |
| Female | 23,634 | 1.02 | 1.00-1.04 |
| Vasopressors | | | |
| Yes | 16,721 | 1.02 | 1.00-1.04 |
| No | 32,610 | 1.00 | 0.98-1.02 |
| Admission source | | | |
| Home | 33,464 | 1.01 | 0.99-1.03 |
| Other | 15,867 | 1.00 | 0.98-1.03 |
| Comorbidities | | | |
| Congestive heart failure | 10,092 | 1.00 | 0.97-1.04 |
| Hemodialysis | 5,207 | 1.00 | 0.96-1.04 |
| Chronic respiratory failure | 5,738 | 0.99 | 0.95-1.02 |
| Source of infection | | | |
| Respiratory | 19,839 | 1.01 | 0.98-1.04 |
| Urinary | 13,439 | 1.01 | 0.98-1.04 |
| Other | 16,053 | 1.01 | 0.99-1.03 |
| Bacteremia | | | |
| Gram positive | 7,175 | 1.03 | 0.99-1.06 |
| Gram negative | 6,431 | 0.99 | 0.96-1.03 |
| Other | 965 | 1.03 | 0.94-1.13 |
| None | 34,757 | 1.00 | 0.99-1.02 |

OR hospital mortality for each hour delay



**NY state
 49331 pts
 149 hosp**

A. INITIAL RESUSCITATION

Rhodes et al
ICM 2017
CCM 2017

2. We recommend that, in the resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 h (strong recommendation, low quality of evidence).

The good

- Emphasis on Fluid resuscitation
- Amount in agreement with observational data

The bad

- No strong data
- One size fits all?

The ugly

- Why delaying therapy?

A. INITIAL RESUSCITATION

1. Sepsis and septic shock are medical emergencies, and we recommend that treatment and resuscitation begin immediately (BPS).
2. We recommend that, in the resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 h (strong recommendation, low quality of evidence).
3. We recommend that, following initial fluid resuscitation, additional fluids be guided by frequent reassessment of hemodynamic status (BPS).



2012 Recommendation for Initial Resuscitation.

We recommend the **protocolized**, quantitative resuscitation of patients with sepsis- induced tissue hypoperfusion. During the first 6 hours of resuscitation, the **goals of initial resuscitation should include all** of the following as a part of a treatment protocol:


- a) CVP 8–12 mm Hg
- b) MAP \geq 65 mm Hg
- c) Urine output \geq 0.5 mL/kg/hr
- d) Scvo2 \geq 70%.

ICM 2015



D. C. Angus
A. E. Barnato
D. Bell
R. Bellomo
C.-R. Chong
T. J.
A. D.
A. D.


A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators



ORIGINAL ARTICLE

Early, Goal-Directed Therapy for Septic Shock — A Patient-Level Meta-Analysis

The PRISM Investigators*



No. at Risk

| | | | | | |
|------------|------|------|------|------|------|
| EGDT | 1857 | 1391 | 1287 | 1209 | 1119 |
| Usual care | 1880 | 1395 | 1295 | 1206 | 1110 |



Rhodes et al
ICM 2017
CCM 2017

Although this protocol cannot now be recommended from its evidence base, bedside clinicians still need guidance as to how to approach this group of patients who have significant mortality and morbidity. We recommend, therefore, that these patients be viewed as having a medical emergency that necessitates urgent assessment and treatment. As part of this, we recommend that initial



EDITORIAL

Early goal-directed therapy: do we have a definitive answer?

Daniel De Backer^{1*} and Jean-Louis Vincent²



Most patient already reached target ScvO₂ values in the recent trials

| | Rivers et al | PROCESS | ARISE | PROMISE |
|---------------------|--------------|---------|-------|---------|
| ScvO ₂ % | 49 | 71 | 73 | 70 |

Rivers et al
NEJM 2001


Angus D et al
NEJM 2014

Peake S et al
NEJM 2014

Mouncey P et al
NEJM 2015

Inclusion: refractory hypotension and/or lactate ≥ 4 (despite fluids)

**Most patients reached ScvO₂ goal at inclusion
and the proposed protocol was not able to
significantly increase this proportion over time !**



Major differences in mortality in control arm

| | Rivers et al | PROCESS | ARISE | PROMISE |
|-----------------------|--------------|---------|-------|---------|
| Mortality % (ctrl) | 50 | 19 | 19 | 29 |
| ScvO ₂ % | 49 | 71 | 73 | 70 |

Rivers et al
NEJM 2001

Angus D et al
NEJM 2014


Peake S et al
NEJM 2014

Mouncey P et al
NEJM 2015

Inclusion: refractory hypotension and/or lactate ≥ 4 (despite fluids)

Prognostic value of lactate and impact of time from diagnosis

Casserly B et al
CCM 43:567;20150



Rivers



28150 pts / 218 sites / SSC database

Inclusion rates ?

Angus D et al
NEJM 2014

- **0.9 Patients/ centre / month** (included)
 - 3.9 Patients/ centre / month** (screened)
- (ED with at least 40000 admissions/ year)**

Peake S et al
NEJM 2014

- **0.5 Patients/ centre / month** (included)
- 1.6 Patients/ centre / month** (screened)


Rowan et al
NEJM 2015

- **0.5 Patients/ centre / month** (included)
- 1.6 Patients/ centre / month** (screened)

20 % of these « septic shock » patients were not admitted to the ICU !?

Angus D et al
ICM 20145

A ICU admission^a



Inclusion: refractory hypotension and/or lactate ≥ 4 (despite fluids)

EDITORIAL

Early goal-directed therapy: do we have a definitive answer?



Daniel De Backer^{1*}  and Jean-Louis Vincent²

- **The concept remains valid**
- **Patient identification is crucial**
- **The classical EGDT may be applied when better hemodynamic strategies cannot be used**

3. We recommend that, following initial fluid resuscitation, additional fluids be guided by frequent reassessment of hemodynamic status (BPS).

Remarks Reassessment should include a thorough clinical examination and evaluation of available physiologic variables (heart rate, blood pressure, arterial oxygen saturation, respiratory rate, temperature, urine output, and others, as available) as well as other noninvasive or invasive monitoring, as available.

**Rhodes et al
ICM 2017
CCM 2017**

The good

- **Integrates other variables of tissue hypoperfusion to indicate fluids**
- **No rigid follow up of EGDT bundles**

The bad

- **No strong data**
- **Too evasive**

The ugly

- **No clear recommendation**

In practice ?

Rhodes et al
ICM 2017
CCM 2017

A. INITIAL RESUSCITATION

3. We recommend that, following initial fluid resuscitation, additional fluids be guided by frequent reassessment of hemodynamic status (BPS).

What do you recommend to your junior doctors, ED colleagues, nurses,...?

Variables to use to indicate further fluid administration?

- **Heart rate / blood pressure**
- **Skin mottling**
- **CVP**
- **Lactate**
- **Veno-arterial PCO₂ gradients**
- **Urine output**
- **Echo**
- **Other available hemodynamic measurements**

Most of these variables indicate poor tissue perfusion not that the patient will respond to fluids !

A. INITIAL RESUSCITATION

4. We recommend further hemodynamic assessment (such as assessing cardiac function) to determine the type of shock if the clinical examination does not lead to a clear diagnosis (BPS).



Maurizio Cecconi
Daniel De Backer
Massimo Antonelli
Richard Beale
Jan Bakker
Christoph Hofer
Roman Jaeschke
Alexandre Mebazaa
Michael R. Pinsky
Jean Louis Teboul
Jean Louis Vincent
Andrew Rhodes

Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine



The Intensive Connection

| No. | Statement/recommendation | GRADE level of recommendation; quality of evidence | Type of statement |
|-----|---|--|-------------------|
| 13. | We recommend further hemodynamic assessment (such as assessing cardiac function) to determine the type of shock if the clinical examination does not lead to a clear diagnosis | Ungraded | Best practice |
| 14. | We suggest that, when further hemodynamic assessment is needed, echocardiography is the preferred modality to initially evaluate the type of shock as opposed to more invasive technologies | Level 2; QoE moderate (B) | Recommendation |
| 15. | In complex patients, we suggest to additionally use pulmonary artery catheterization or transpulmonary thermodilution to determine the type of shock | Level 2; QoE low (C) | Recommendation |

A. INITIAL RESUSCITATION

5. We suggest that dynamic over static variables be used to predict fluid responsiveness, where available (weak recommendation, low quality of evidence).



Dynamic variables to predict the response to fluids?

=> Evaluation of preload responsiveness during transient change in preload induced by respiration or external maneuver



Dynamic variables to predict the response to fluids?

Heart-lung interactions


- **Respiratory variations in stroke volume**
- **Respiratory variations in vena cava size**
- **Expiratory pause**

External maneuvers

- **Passive leg raising test**

SEPSIS

Michard et al
AJRCCM 162:134;2000



N= 40

Cut-off value: 13%

DDB

Table 12. Pulse pressure variation in predicting fluid responsiveness in patients with sepsis or septic shock



| Sensitivity | 0.72 (95% CI: 0.61 to 0.81) | | | Prevalence | | 40% ⁵ | | | |
|--|---------------------------------|--|---|-----------------------------|---------------|----------------------|---------------------|---|-------------------------|
| Specificity | 0.91 (95% CI: 0.83 to 0.95) | | | | | | | | |
| Outcome | № of studies (№ of patients) | Study design | Factors that may decrease quality of evidence | | | | | Effect per 1,000 patients tested pre-test probability of 40% | Test accuracy QoE |
| | | | Risk of bias | Indirectness | Inconsistency | Imprecision | Publication bias | | |
| True positives (patients with Fluid responsiveness) | 5 studies 219 patients | cross-sectional (cohort type accuracy study) | serious ¹ | not serious | not serious | serious ² | none | 288 (244 to 324) | ⊕⊕○○ LOW |
| False negatives (patients incorrectly classified as not having Fluid responsiveness) | | | | | | | | 112 (76 to 156) | |
| True negatives (patients without Fluid responsiveness) | 5 studies 219 patients | cross-sectional (cohort type accuracy study) | serious ¹ | not serious ³ | not serious | serious ⁴ | none | 546 (498 to 570) | ⊕⊕○○ LOW |
| False positives (patients incorrectly classified as having Fluid responsiveness) | | | | | | | | 54 (30 to 102) | |

1. We downgraded the quality of evidence for risk of bias by one level, most studies were at high risk of bias with QUADAS Tool
2. We downgraded the quality for imprecision by one level, 112 per 1000 tested patients will have a false negative results, the CI of pooled sensitivity was wide
3. Although the reference test was not a static measure in included studies, we did not downgrade the quality of evidence because we can indirectly compare with other static measures
4. We downgraded the quality of evidence by one level for imprecision, small number of patients and the CI of the pooled specificity included values below the desired threshold
5. Prevalence of fluid responsiveness is estimated to be 40%, data from Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? JAMA. 2016;316(12):1298-309.

RESEARCH

Open Access


Preload dependence indices to titrate volume expansion during septic shock: a randomized controlled trial



**CVP: Never an optimal prediction but still
some reasonable guidance if nothing
better can be used....**


| CVP cut-off point (mmHg) | Number of data sets for the CVP ranges given | Positive predictive value | Negative predictive value |
|--------------------------|--|---------------------------|---------------------------|
| 0 | <2: 72 | 64 % (39–89) | 52 % (49–55) |
| 2 | 2–3: 125 | 65 % (54–76) | 53 % (50–56) |
| 4 | 4–5: 163 | 64 % (57–71) | 55 % (52–59) |
| 6 | 6–7: 177 | 59 % (54–65) | 57 % (54–61) |
| 8 | 8–9: 187 | 56 % (52–61) | 59 % (56–63) |
| 10 | 10–11: 161 | 53 % (50–57) | 61 % (56–66) |
| 12 | 12–13: 108 | 51 % (47–54) | 61 % (55–67) |
| 14 | 14–15: 79 | 50 % (47–53) | 66 % (58–73) |
| 16 | 16–17: 39 | 49 % (46–52) | 64 % (54–75) |
| 18 | 18–19: 22 | 48 % (45–51) | 59 % (44–75) |
| 20 | >19: 15 | 48 % (45–51) | 53 % (28–79) |

**CVP: Never an optimal prediction but still
some reasonable guidance if nothing
better can be used....**



556 pts

**CVP: Never an optimal prediction but still
some reasonable guidance if nothing
better can be used....**



556 pts

F. FLUID THERAPY

1. We recommend that a fluid challenge technique be applied where fluid administration is continued as long as hemodynamic factors continue to improve (BPS).




A. INITIAL RESUSCITATION

6. We recommend an initial target mean arterial pressure (MAP) of 65 mm Hg in patients with septic shock requiring vasopressors (strong recommendation, moderate quality of evidence).

High vs Low MAP ?

Asfar P et al
NEJM 2014

65-70 VS 80-85 mmHg




798 pts septic shock


A. INITIAL RESUSCITATION

7. We suggest guiding resuscitation to normalize lactate in patients with elevated lactate levels as a marker of tissue hypoperfusion (weak recommendation, low quality of evidence).






Lactate guided
therapy



Lactate guided therapy (-20%/2h for 8h)

Janssens T et al
AJRCCM 2010



Adjusted analysis - hazard ratio (95% CI)^s

| | | | | |
|-----------------------|--|------------------|--|-------|
| In-hospital mortality | | 0.61 (0.43-0.87) | | 0.006 |
| 28-day mortality | | 0.75 (0.52-1.09) | | 0.134 |
| ICU-mortality | | 0.66 (0.45-0.98) | | 0.037 |



N=348



Wan-Jie Gu
Zhongheng Zhang
Jan Bakker

Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials

Accepted: 8 June 2015

the potential to be such a promising goal for quantitative resuscitation. We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the effect of early lactate clearance-guided therapy on mortality and other outcomes in patients with sepsis.

We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials to identify RCTs that evaluated the effect of early lactate clearance-guided therapy on clinical outcomes in adults with

event proportion obtained from the results of the meta-analysis, and a relative risk reduction of 20 % in all-causes mortality, using standard software TSA version 0.9 Beta (<http://www.ctu.dk/tsa>).

Four RCTs enrolling 547 patients were included in the meta-analysis [2–5]. The main characteristics of the four included RCTs are presented in Table 1 in the Electronic Supplementary Material (ESM). Assessment of the risk of bias is summarized in Table 2 (ESM). Overall, two RCTs




Fig. 1 Forest plot depicting mortality




Use of stepwise lactate kinetics-oriented hemodynamic therapy could improve the clinical outcomes of patients with sepsis-associated hyperlactatemia

Xiang Zhou¹, Dawei Liu^{1*}, Longxiang Su¹, Bo Yao², Yun Long¹, Xiaoting Wang¹, Wenzhao Chai¹, Na Cui¹, Hao Wang¹ and Xi Rui¹

Crit Care 2016

**60 day mortality:
28 vs 18%
p=0.033**

N=360




A. INITIAL RESUSCITATION

7. We suggest guiding resuscitation to normalize lactate in patients with elevated lactate levels as a marker of tissue hypoperfusion (weak recommendation, low quality of evidence).



Lactate-guided resuscitation saves lives: we are not sure

Bakker – De Backer -Hernandez
ICM 2016



FLUID THERAPY



F. FLUID THERAPY

2. We recommend crystalloids as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock (strong recommendation, moderate quality of evidence).
3. We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock (weak recommendation, low quality of evidence).




F. FLUID THERAPY

4. We suggest using albumin in addition to crystalloids for initial resuscitation and subsequent intravascular volume replacement in patients with sepsis and septic shock when patients require substantial amounts of crystalloids (weak recommendation, low quality of evidence).




Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials

The effect of albumin on 90-day mortality in patients with severe sepsis.



The effect of albumin on 90-day mortality in patients with septic shock.



F. FLUID THERAPY

5. We recommend against using hydroxyethyl starches (HESs) for intravascular volume replacement in patients with sepsis or septic shock (strong recommendation, high quality of evidence).
6. We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock (weak recommendation, low quality of evidence).



VASOPRESSOR SUPPORT



Rhodes et al
ICM 2017
CCM 2017

When to introduce vasopressors?




When to introduce vasopressors?



**Early introduction of vasopressors may
decrease later need for fluids**



**Early introduction of norepi
decreased fluids requirements**

**Sennoun N et al
CCM 35:1736;2007**



Duration of hypotension before initiation of vasopressor agents is associated with poor outcome

Bai X et al
Crit Care 2014



213 pts with septic shock


G. VASOACTIVE MEDICATIONS

1. We recommend norepinephrine as the first-choice vasopressor (strong recommendation, moderate quality of evidence).



Norepinephrine vs Dopamine in shock (SOAP investigators)

De Backer et al
NEJM 362: 779; 2010




No. at Risk

| | | | | | | | | |
|----------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Norepinephrine | 821 | 617 | 553 | 504 | 467 | 432 | 412 | 394 |
| Dopamine | 858 | 611 | 546 | 494 | 452 | 426 | 407 | 386 |

Dopamine vs norepinephrine in septic shock

A meta-analysis

De Backer et al
CCM 40:725:2012




Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock

Vail E et al
JAMA 2017

Emily Vail, MD; Hayley B. Gershengorn, MD; May Hua, MD, MSc; Allan J. Walkey, MD, MSc; Gordon Rubenfeld, MD, MSc; Hannah Wunsch, MD, MSc

Shifting from norepi to phenylephrine + dopamine was associated with increased mortality

B Shortage hospitals (26 hospitals)
Baseline period



| Cohort | Deaths, No./Total Patients, No. (%) | Absolute Mortality Difference, % (95% CI) ^a | Adjusted Odds Ratio (95% CI) ^b | P Value |
|--|-------------------------------------|--|---|---------|
| Patients with septic shock receiving vasopressors | | | | |
| Primary model ^c | | | | |
| Admission to shortage hospitals during a nonshortage quarter | 9283/25 874 (35.9) | NA | 1 [Reference] | |
| Admission to shortage hospitals during a quarter of 2011 in which norepinephrine use decreased >20% below baseline | 777/1961 (39.6) | 3.7 (1.5-6.0) | 1.15 (1.01-1.30) | .03 |


G. VASOACTIVE MEDICATIONS

2. We suggest adding either vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) or epinephrine (weak recommendation, low quality of evidence) to norepinephrine with the intent of raising MAP to target, or adding vasopressin (up to 0.03 U/min) (weak recommendation, moderate quality of evidence) to decrease norepinephrine dosage.



VASST

Russell et al
NEJM 358:877;2008




802 septic shock pts

VASST


Russell et al
NEJM 358:877;2008

Mortality (%) according to severity at baseline



More severe n= 400
(NE > 15 mcg/min)

(15 mcg/min ~0.19 - 0.21 mcg/kg.min for 80-70kg pts)




Less severe n= 378
(NE < 15 mcg/min)

Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock The VANISH Randomized Clinical Trial

Anthony C. Gordon, MD; Alexina J. Mason, PhD; Neeraja Thirunavukkarasu, MSc; Gavin D. Perkins, MD; Maurizio Cecconi, MD; Magda Cepkova, MD; David G. Pogson, MB BCh; Hollmann D. Aya, MD; Aisha Anjum, BSc; Gregory J. Frazier, MSc; Shalini Santhakumaran, MSc; Deborah Ashby, PhD; Stephen J. Brett, MD; for the VANISH Investigators

Gordon et al
JAMA 2016

A double-blind randomised controlled trial of vasopressin (up to 0.06 u/min) vs noradrenaline within 6h of onset of septic shock.



Norepi dose at randomization: 0.16 [0.10-0.31] mcg/kg.min

ORIGINAL ARTICLE

Angiotensin II for the Treatment of Vasodilatory Shock

Ashish Khanna, M.D., Shane W. English, M.D., Xueyuan S. Kealy Ham, M.D., James Tumlin, M.D., Harold Szerlip, M.D., Laurence W. Busse, M.D., Laith Altaweel, M.D., Timothy E. Albertson, M.D., M.P.H., Ph.D., Caleb Mackey, M.D., Michael T. McCurdy, M.D., David W. Boldt, M.D., Stefan Chock, M.D.

The primary end point was the response with respect to mean arterial pressure at hour 3, with response defined as a mean arterial pressure of 75 mm Hg or higher or an increase in mean arterial pressure from baseline of at least 10 mm Hg, without an increase in the dose of background vasopressors. The mean values of triplicate deter-

| End Point | Angiotensin II (N=163) | Placebo (N=158) | Odds or Hazard Ratio (95% CI) | P Value |
|--|------------------------|-----------------|--------------------------------|---------|
| Primary efficacy end point: MAP response at hour 3 — no. (%)† | 114 (69.9) | 37 (23.4) | Odds ratio, 7.95 (4.76–13.3) | <0.001 |
| Secondary efficacy end points | | | | |
| Mean change in cardiovascular SOFA score at hour 48‡ | -1.75±1.77 | -1.28±1.65 | | 0.01 |
| Mean change in total SOFA score at hour 48§ | 1.05±5.50 | 1.04±5.34 | | 0.49 |
| Additional end points | | | | |
| Mean change in norepinephrine-equivalent dose from baseline to hour 3¶ | -0.03±0.10 | 0.03±0.23 | | <0.001 |
| All-cause mortality at day 7 — no. (%) | 47 (29) | 55 (35) | Hazard ratio, 0.78 (0.53–1.16) | 0.22 |
| All-cause mortality at day 28 — no. (%) | 75 (46) | 85 (54) | Hazard ratio, 0.78 (0.57–1.07) | 0.12 |

Thank you

IMPROVE
-MENT